NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Published: 12 January 2024
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
https://www.nature.com/articles/s43018-023-00709-6

Our study suggests that the combination of CAR T cells and PD-1 inhibition in GBM is safe and biologically active but, given the lack of efficacy, also indicates a need to consider alternative strategies.

Kudos to @StephenBagleyMD, Zev Binder, Donald M. O'Rourke and our team of collaborators for the publication today @NatureCancer on the Phase 1 study of CAR T cell therapy with #pembrolizumab, showing biological activity in the #TME, but limited clinical efficacy, pointing to… pic.twitter.com/sLr5HyoMfd

— Steven Brem (@StevenBremMD) January 12, 2024